諾誠健華(09969.HK)「奧布替尼」於廣州生產並發貨至全國30個省份
諾誠健華(09969.HK)公布,廣州諾誠健華醫藥科技獲批商業化生產後,已快速實現「宜諾凱」(奧布替尼)的生產,現時向北京、廣東、江蘇等30個省份、自治區及直轄市供應該款創新藥,標誌著公司實現從自主研發、自主銷售到自主生產的研產銷一體化的全產業鏈平台。
諾誠健華聯合創始人、董事長兼CEO崔霽松指,廣州公司將有助於夯實研產銷一體化實力,未來將不斷提升創新和生產能力,為廣州打造全球生物醫藥產業新高地、為大灣區構建全球科技創新高地作出貢獻。(gc/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.